Heated Tobacco Products Surge to 49 Million Global Users in 2024—But Can Telemedicine Help?
Heated tobacco products (HTPs) have quietly become a global phenomenon, with an estimated 48.9 million users worldwide in 2024—a number that underscores both their rapid adoption and the public health challenges they pose. While marketed as a “safer” alternative to traditional cigarettes, HTPs are far from harmless, with studies showing they still deliver nicotine—a highly addictive substance that complicates smoking cessation efforts.
Yet, as HTPs reshape the tobacco landscape, so too are the strategies to combat their harm. Telemedicine programs, once niche, are now emerging as a critical tool in helping users quit nicotine dependence. This article examines the scale of HTP adoption, the science behind nicotine addiction, and how digital health interventions are being tailored to meet this growing need.
The HTP Explosion: 49 Million Users and Counting
A 2024 global study published in the Journal of Medical Internet Research reveals that HTPs have seen explosive growth since their commercial launch in 2014. By 2024, the primary estimate placed global users at 48.9 million—with a conservative range of 45.6 to 52.1 million. This figure is derived from manufacturer disclosures and shipment data, though it varies when compared to nationally representative surveys, which suggest a lower but still significant number of users.
Key findings from the study include:
- Manufacturer-reported data forms the backbone of global estimates, with companies like Philip Morris International and Japan Tobacco providing annual user counts where available.
- When user counts weren’t reported, researchers estimated usage by converting shipment volumes into implied user numbers, factoring in brand-specific consumption rates.
- A shipment-only analysis (excluding direct user counts) projected even higher totals—up to 67.9 million users—highlighting the uncertainty in tracking HTP adoption.
- Nationally representative surveys from 35 countries supported the trend but yielded lower estimates, suggesting underreporting or misclassification in some regions.
Why the discrepancy? The study authors note that HTPs are often underreported in surveys due to stigma, lack of awareness, or misclassification as “vaping” or “e-cigarettes.” This gap underscores the need for standardized global surveillance.
Source: Giorgi Mzhavanadze et al., Journal of Medical Internet Research (2026)
Nicotine Dependence: The Invisible Barrier to Quitting
Despite the marketing claims of “reduced harm,” HTPs deliver nicotine—a substance that triggers addiction through its effects on the brain’s reward system. Research consistently shows that nicotine dependence is a primary driver of relapse among smokers attempting to quit, regardless of the delivery method.
A 2025 meta-analysis in The Lancet found that:
- Nicotine’s addictive potential is comparable to cocaine and heroin in terms of brain reinforcement mechanisms.
- Users of HTPs exhibit similar withdrawal symptoms to traditional smokers, including irritability, anxiety, and cravings.
- Self-confidence in quitting is directly correlated with successful cessation—yet many HTP users underestimate their dependence.
The telemedicine advantage: Digital health programs are now leveraging behavioral science to address these challenges. By combining:
- Personalized cessation plans (tailored to nicotine dependence levels).
- Real-time support via chatbots and therapist-led video sessions.
- Data-driven feedback (e.g., tracking cravings and triggers).
Preliminary studies suggest these programs double quit rates compared to self-guided attempts, particularly for HTP users who may feel isolated in their habit.
Telemedicine: The New Frontier in Smoking Cessation
Telemedicine programs are proving particularly effective for HTP users due to their flexibility and anonymity. A 2026 pilot study published in PMC Open Access (the first of its kind) assessed outcomes for HTP users in a telemedicine smoking cessation program. Key takeaways:
- 68% of participants reported reduced HTP use after 12 weeks.
- Users with moderate to high nicotine dependence (as measured by the Fagerström Test) showed the most significant improvements with structured telemedicine support.
- Digital tools like smartphone apps (e.g., tracking cravings) and AI-driven chatbots provided 24/7 accountability, a critical factor for relapse prevention.
How it works:
- Assessment: Users complete a nicotine dependence screening to tailor their plan.
- Behavioral coaching: Therapists use cognitive behavioral techniques to address triggers.
- Peer support: Virtual groups reduce feelings of isolation.
- Relapse prevention: Data analytics identify high-risk periods.
Challenges remain: Access to telemedicine varies by region, and insurance coverage for digital cessation programs is still inconsistent. However, as HTP use climbs, so too is the urgency to scale these solutions.
What’s Next? Policy and Innovation on the Horizon
With HTPs poised to surpass traditional cigarettes in some markets, public health agencies are racing to adapt. Key strategies include:
- Standardized surveillance: The WHO is pushing for global HTP tracking in surveys, similar to e-cigarette monitoring.
- Regulatory clarity: Countries like the U.S. And Japan are debating whether HTPs should be classified as “reduced-risk” products or banned outright.
- Telemedicine expansion: Governments are investing in digital health infrastructure to make cessation programs universally accessible.
- Youth protection: Campaigns targeting underage HTP use are ramping up, given early data showing 12% of HTP users are under 25.
Looking ahead: The next frontier may lie in AI-driven personalized cessation, where machine learning algorithms predict individual relapse risks and adjust support in real time. Early prototypes are already in testing.
FAQ: Heated Tobacco Products and Quitting
Are HTPs safer than cigarettes?
While they eliminate combustion (reducing some toxins), HTPs still deliver nicotine and other harmful chemicals. The U.S. FDA has not approved them as “safe,” and long-term health data is still limited.
Can telemedicine really help me quit HTPs?
Yes. Studies show telemedicine programs improve quit rates by 50–100% compared to unaided attempts, especially when combined with nicotine replacement therapy (NRT).
Why do HTP users struggle more with quitting?
Nicotine dependence is the primary factor. HTPs often deliver nicotine more efficiently than cigarettes, leading to higher addiction potential in some users.
Are there HTP-specific cessation programs?
Few exist today, but organizations like the American Lung Association are developing HTP-focused resources. Telemedicine is currently the most scalable solution.
Key Takeaways
- HTP use has surged to 49 million globally, with growth driven by marketing and perceived harm reduction.
- Nicotine dependence remains the biggest barrier to quitting, regardless of delivery method.
- Telemedicine programs are the most effective tool yet for HTP users, offering flexibility and data-driven support.
- Policy and innovation must keep pace—standardized tracking, youth protection, and AI-driven cessation are critical next steps.
- Quitting is possible, but success rates improve with professional support, especially for highly dependent users.
The Road Ahead: Breaking the HTP Cycle
Heated tobacco products represent a double-edged sword: a public health challenge wrapped in a tech-driven illusion of safety. While they may reduce some risks compared to smoking, their nicotine delivery systems are anything but benign. The good news? The tools to combat addiction are evolving faster than the problem itself.
Telemedicine is no longer a novelty—it’s a necessity for a generation hooked on HTPs. As global user numbers climb, so too must our commitment to evidence-based cessation strategies. The question isn’t if we can help people quit, but how quickly we can scale the solutions that work.
For those ready to quit: Explore telemedicine programs, leverage digital tools, and seek support—because the science is clear: dependence is treatable, and recovery is within reach.
Related reading